Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Phase 2b Study to Compare the Efficacy of DSP107 in Combination With Atezolizumab Versus Fruquintinib in Patients With Advanced Microsatellite Stable Colorectal Cancer

NCT07235293 is registered in ClinicalTrials.gov with Kahr Bio Australia Pty Ltd as lead sponsor.

NCT NCT07235293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07235293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Phase 2b Study to Compare the Efficacy of DSP107 in Combination With Atezolizumab Versus Fruquintinib in Patients With Advanced Microsatellite Stable Colorectal Cancer
Lead sponsor
Kahr Bio Australia Pty Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
January 16, 2026
Completion date
April 30, 2027
Enrollment
90 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer